Advanced NSCLC harboring either ALK or ROS1 fusion can be effectively treated with tyrosine kinase inhibitors (TKIs) targeting ALK or ROS1, respectively, and several ALK/ROS1 tyrosine kinase inhibitors (TKIs) are now approved by the United States Food and Drug Administration. This evidence concerns the gene ALK and non-small cell lung carcinoma.